EHA-Balkan Hematology Day 2024

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 5th edition of the EHA-Balkan Hematology Day.

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

EHA Grants Hall of Fame

EHA: Bridging Breakthroughs in Hematology

The European Hematology Association (EHA) has undergone a remarkable transformation over the past two years, positioning itself as a future-ready organization dedicated to addressing the needs of the European hematology community.

EHA-BMSH Balkan Hematology Tutorial

EHA is joining the Bulgarian Medical Society of Hematology (BMSH) to organize the EHA-BMSH Balkan Hematology Tutorial on Myeloproliferative Neoplasms.

EHA Diagnosis - Coming in 2024

EHA Diagnosis is a new digital tool that EHA has created exclusively for our members.

EHA-GBMTA-AHA Hematology Tutorial

EHA is joining the Georgian Association for Blood and Bone Marrow Transplantation (GBMTA) and Armenian Hematology Association (AHA) to organize the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies.

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.